TrialThe Lancet. Oncology2014

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.

Harpreet Wasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.